Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.41 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7621104 | 0.84 | OPRM1 (0.48) | OPRM1SIGMAR1KDM4EALDH1A1CYP2D6 | |
| SCHEMBL7622012 | 0.83 | OPRM1 (0.52) | OPRM1SIGMAR1KDM4EALDH1A1CYP2D6 | |
| SCHEMBL6603001 | 0.79 | OPRM1 (0.47) | OPRM1SIGMAR1ALDH1A1CYP2D6TSHR | |
| SCHEMBL7618792 | 0.76 | SIGMAR1 (0.32) | SIGMAR1 | |
| SCHEMBL14722834 | 0.72 | NPFFR1 (0.50) | NPFFR1NPFFR2BCHEACHEALDH1A1 | |
| SCHEMBL7495543 | 0.71 | KDM4E (0.41) | KDM4EBCHEACHE | |
| SCHEMBL17606613 | 0.71 | OPRL1 (0.48) | OPRM1SIGMAR1NPFFR1NPFFR2BCHE | |
| SCHEMBL7625839 | 0.70 | OPRM1 (0.45) | OPRM1SIGMAR1ALDH1A1CYP2D6TSHR | |
| SCHEMBL25876550 | 0.70 | KDM4E (0.46) | OPRM1SIGMAR1KDM4EBCHEACHE | |
| SCHEMBL7815159 | 0.69 | ALDH1A1 (0.46) | OPRM1SIGMAR1ALDH1A1CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | IKEDA TAKAFUMI (JP) | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | OPRM1 42/4885SIGMAR1 127/4885KDM4E 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.